OUR STORY
An American Biotech R+D laboratory based in Fair Lawn, New Jersey, specializing in anti-aging and aesthetic skincare platforms for clinical professionals and consumers alike
A WOMEN-OWNED ENTERPRISE STRIVING FOR PERFECTION
As a privately owned American personal care company, our passion lies in producing innovative, comprehensive aesthetic anti-aging solutions and topical skin treatments. We cater to the demands of medical professionals, cosmeticians, and skincare markets worldwide, empowering them with cutting-edge products that redefine the limits of beauty science. Join us on this exhilarating journey as we redefine the future of skincare and unlock the secrets of timeless radiance.
Welcome to the future of beauty. Welcome to ABG LAB.
DEDICATION TO EXCELLENCE
/w=1080,quality=80)
At ABG Lab, our dedication extends beyond the creation of superior products. We stand resolute in our stringent standards, channeling relentless precision into every facet of our intradermal aesthetic treatments. From inception to final delivery, our approach is underpinned by international quality and regulatory benchmarks. Our formulations embody the latest scientific insights and pioneering technologies within the aesthetic realm, ensuring unparalleled results and safety.
A LOOK AT OUR HISTORY
ABG LAB is a privately owned American biotechnology research & development laboratory based in Fair Lawn, New Jersey, focusing on anti-aging & aesthetic skincare technologies.
With exclusive, proprietary formulations and intradermal aesthetic solutions administered to millions of satisfied patients worldwide, ABG Lab’s anti-aging technology repertoire includes a range of anti-aging aesthetic treatments and proprietary skincare solutions. Among ABG LAB’s most successful technologies is its flagship MESO-WHARTON P199®, the only Stem Cell Active Wharton’s Jelly peptide to reverse skin aging and restore health to damaged skin. MESO-WHARTON P199® has demonstrated outstanding clinical results in over one million patients worldwide since its introduction in 2010.
Continuing its trailblazing advancements, ABG Lab proudly introduced MESO-XANTHIN F199® as a first of it’s kind regenerative epigenetic treatment. This revolutionary therapy is a cellular revitalization tonic, specifically targeting fibroblasts and epidermal skin cells. MESO-XANTHIN F199 plays a pivotal role in preserving the youthfulness, vitality, and optimal functionality of these cells.
In 2014, ABG Lab launched MESOEYE C71® and MESOSCULPT C71® as part of its anti-aging arsenal to restore youthful facial beauty. MESOEYE C71 focuses on the eye area by effectively treating eye bags, under-eye puffiness, dark circles, and deep crow’s feet wrinkles. MESOSCULPT C71 shrinks facial fat deposits in the chin, jawline, and cheeks to restore a more youthful facial contour, restoring the classic facial triangle of beauty.
ABG Lab's history attests to its commitment to delivering precise and effective solutions that cater to the unique needs of individuals seeking to restore their youthful skin.
PURPOSE-DRIVEN SCIENCE
At ABG Lab, our foundational principles rest on dual pillars: to instill individuals with the self-assurance that emanates from robust, luminous skin and to elevate the clinical outcomes of medical practitioners using our avant-garde solutions. Grounded in the advanced science of stem cells, epigenetics, microcirculation, and autophagy, our offerings redefine skincare conventions.
We not only aspire to rejuvenate your skin and attenuate the ravages of time but also to protect it from further compromise. This ambition isn't just for today but shapes our forward-thinking approach. By arming clinical experts with state-of-the-art interventions, we amplify our core ethos, touching lives with the revolutionary capacities of our sophisticated technologies. United, we're forging a novel skincare trajectory, eliciting confidence and revitalization on a global scale.
VISIONARY OUTLOOK
ABG Lab’s vision is responsible for its rapid ascendancy to the upper echelons of anti-aging treatment providers. ABG Lab’s mission statement is, first and foremost, to develop safe & optimal regenerative solutions and anti-aging skincare platforms.
ABG Lab projects a leadership role in the vanguard of skincare advancement. Our unwavering dedication is to lead the sector with unmatched aesthetic solutions that align seamlessly with diverse clinical aspirations. We're reshaping the established norms of skincare, empowering individuals to reclaim their skin's youthful vigor without resorting to drastic interventions.
Our innovative offerings, infused with the amalgamation of stem cells, epigenetics, microcirculation, and autophagy, deliver transformative results. Committed to rekindling the skin's innate luminosity, reducing the manifestations of age, and fortifying it against external threats, ABG Lab envisions a horizon where our groundbreaking innovations redefine skincare norms, cultivating global assurance and radiant vitality.
MEET THE TEAM
Elina Tester
Founder & CEO
An American businesswoman, scientist, and creator of some of the most advanced breakthrough developments in anti-aging skincare technologies. Elina Tester serves as President & CEO of ABG LAB. She has over two decades of experience developing and bringing cutting-edge skincare and aesthetic technologies to life.
As the President and CEO of ABG Lab, Dr. Tester is internationally renowned for her revolutionary anti-aging technologies and treatments. Dr. Tester has over 15 years of experience spearheading the development of an array of cutting-edge skincare technologies that have revolutionized how doctors can choose to treat the signs of a prematurely aged face showing signs of skin damage.
Her passion has been working on introducing new aesthetic treatments and topical skincare technologies to the market—ABG Lab’s repertoire of anti-aging solutions is a testament to her collaboration with renowned laboratories, esteemed colleagues, and a dedicated team.
Louis Rinaldi
Vice President
Louis Rinaldi brings to ABG LAB the culmination of multiple decades of bright and fruitful experience in dietary supplements, topical skincare, and anti-aging technologies. After serving as Chief Cosmetic Officer for a multi-million dollar Fortune 500 company, he has brought solid experience and expertise in marketing, regulatory affairs, and media communications.
His strong and successful career path includes a key role in marketing, global media communications, and launching internationally known products, including the Strivectin skincare brand, Hylexin, Lumedia, and Amatokin, the first stem cell activating face cream.
Serving as Vice President of ABG Lab has allowed us to build upon his great wisdom and communication channels. He has helped us bring numerous formidable anti-aging technologies to market.
David Ott
Chief Scientific Officer
As a brilliant laboratory scientist and innovator, David Ott has been the Chief Scientific Officer for ABG Lab since the company’s founding. After completing his studies in microbiology and cosmetic science, David has excelled in creating dynamic new topical skin and hair products. He has a keen eye for innovative research and potential new anti-aging technologies.
After playing a vital role in developing Polypeptide 1— the first stem cell activating peptide, he assisted ABG Lab in developing Meso-Xanthin F199® and the new LipoBlock XP2® Complex. His achievements and record speak for themselves and are paramount to the accomplishments at ABG Lab. A vital force in the research arm of ABG Lab as it pioneers revolutionary anti-aging solutions.
Michael Kane
Chief Medical Director
Dr. Kane is known for pioneering work with injectables for cosmetic purposes while a fellow at the Manhattan Eye, Ear & Throat Hospital. Over the past twenty years, Dr. Kane taught thousands of physicians how to administer injectables properly through lectures and live demonstrations.
Dr. Kane went to film school before he went to medical school. So perhaps this artist’s eye combined with a surgeon’s precision led him to a new conclusion on skincare and its effects. After his medical studies, Dr. Kane entered a general surgery residency at New York Medical College. During this residency, based at Lincoln Hospital in the Bronx, Dr. Kane provided sophisticated surgical care to patients affected by the urban violence that plagued this area in the 1980s.
Dr. Kane is also a distinguished authority on correcting the tear trough and lower eyelid area using fillers. He authored the first scientific paper on this technique and continues to lecture worldwide on the subject.
Boris Petrikovsky
Senior Scientific Advisor
A world-renowned, board-certified OB/GYN physician (M.D., Ph. D.) specialist in fetal medicine and surgery—he serves as a member of the editorial board of the Journal of Neonatal Intensive Care. His major research interests include fetal medicine, prenatal diagnosis, fetoscopy, fetal cardiology, OB/GYN sonography, and invasive OB/GYN procedures.
He was the first in the world to perform in-utero platelet transfusion, in the rare case of a congenital fetal problem, with excellent results. Dr. Petrikovsky pioneered a patented new technique for transcervical endoscopy, which allows for direct visualization and treatment of the fetus when membranes are ruptured. He has published over 100 peer-reviewed articles and ten book chapters, as well as Fetal Disorders, a best-selling textbook on fetal medicine and treatment. He is the recipient of the Recognition Award of the Brooklyn Gynecologic Society, the Howard Levine M.D. Science Award from the Obstetrical Society of Boston, the Bristol-Myers Squibb/Mead Johnson Traveling Fellowship, and the Italian Society of Perinatal Medicine Award.
